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Abstract 
Background: Fatigue is a common and distressing cancer symptom that negatively affects the quality 
of life. Many scales have been developed to assess cancer-related fatigue. The properties of the scales 
vary in terms of dimensionality, reliability, validity, length, and method of administration. Insufficient 
of psychometric properties may affect the accuracy of scales findings, that may lead result obtained 
questionable. The main objective of this review was to conduct a quality assessment of the 
psychometric properties of cancer-related fatigue scales to identify appropriate scales that could be 
used in research and clinical practice. 
Method: A systematic search was carried out to identify validated scales that measure cancer-related 
fatigue. Five databases were searched: CINAHL, MEDLINE, EMBASE, PsycINFO, Cochrane 
Library. This review was conducted following the PRISMA and Terwee et al.’s quality assessment 
guidelines to evaluate the psychometric properties of the studies.  
Result: Seventy-one different studies published between 1970 and 2018 met the inclusion criteria. 
Twenty-five scales were identified. Of these, eighteen were multidimensional and seven were uni-
dimensional, containing between 4 and 72 items. Reliability and/or validity information was missing 
for many scales. Four scales met the quality assessment criteria and were reported as the most 
appropriate for measuring fatigue in cancer patients.  
Conclusion: Further psychometric testing is required for other scales. Developing a universally-
defined tool kit for the assessment of cancer-related fatigue may help clarify the concept of fatigue 
and promote a systematic approach to fatigue measurement. 
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Introduction 
A cancer diagnosis is a major life stressor that affects an individual’s physiological and 
psychological state. Patients may experience symptoms related to their cancer and/or cancer treatment 
with fatigue being a common and distressing symptom. Estimated prevalence rates range from 50% 
and 90% [1]. The variation in prevalence among similar cancer patient populations may be partially 
dependent upon how Cancer-Related Fatigue (CRF) is measured. Many cancer patients described 
fatigue highly distressing symptom affecting their quality of life [2,3]. Fatigue occurs during cancer 
diagnosis, treatment and throughout the survival trajectory [4] including long-term disease-free 
survivors [5], and advanced cancer patients [1]. CRF typically increases during radiation  [6], 
chemotherapy [7] , and biological therapy [8]. 
Despite the prevalence of CRF, there is no universally agreed upon definition of CRF or gold 
standard questionnaire to measure this troubling symptom [9]. One of the most commonly cited 
definitions, proposed by the National Comprehensive Cancer Network (NCCN), states that fatigue is 
'a distressing persistent subjective sense of physical, emotional, and/or cognitive tiredness or 
exhaustion related to cancer or cancer treatment that is not proportional to recent activity that 
interferes with usual functioning' [10]. The European Association for Palliative Care (EAPC) defined 
CRF as a 'subjective feeling of tiredness, weakness or lack of energy' [11]. Both definitions described 
CRF as subjective, indicating that the assessment of fatigue should be solicited directly from the 
individual. One difference between the EAPC and NCCN definitions is the impact of CRF on 
functioning, with the latter being more comprehensive to include the consequences of fatigue on 
function. The conceptual definition of CRF should guide the operationalization of outcome measures 
used in research studies. Consequently, the different CRF definitions employed within research 
studies may help explain the variety of scales used to measure fatigue.  
Researchers strive to use CRF scales with acceptable reliability and validity. Insufficient  
reporting or testing of psychometric properties may affect the accuracy of findings, leading to 
questionable study results [12–14]. The use of valid and reliable scales to measure CRF may lead to 
 
 
improvement in patient care and development of fatigue guidelines. Four previous systematic reviews 
have been published which explore the reliability and validity of CRF measuring scales [15–18]. 
Whilst such reviews were helpful, they did not employ any structured quality assessment criteria to 
determine the psychometric properties of the scales being reviewed. Terwee et al. [19] provided 
researchers with quality assessment criteria to evaluate studies that have reported the psychometric 
properties of questionnaires. Hence, the purpose of this review is to assess the psychometric 
properties of CRF scales using the Terwee et al.’s quality assessment criteria.   
Methods 
Search Strategy  
A systematic literature search was conducted using the following electronic databases: 
CINAHL, MEDLINE, EMBASE, PsycINFO, Cochrane Library, for the period from 1946 to 
December 2018. The search strategy used in each database was as follows: (MH "Patient 
Assessment+") OR (MH "Clinical Assessment Tools+") OR (MH "Functional Assessment+") OR 
(MH "Outcome Assessment"); (MH "Outcome Assessment") OR (MH "Measurement Issues and 
Assessments+"); (MH "Inventories"); (MH "Scales"); (MH "Cancer Fatigue") OR (MH "Fatigue 
Syndrome, Chronic"); (fatigue adj (scale or inventory or instrument or measurement or 
assessment)).mp.; (MH "Process Assessment (Health Care) +"); (MH "Clinical Assessment Tools+"); 
(MH "Measurement Issues and Assessments+") OR (MH "Psychometrics"); (MH "Fatigue+"); (MH 
"Hematologic Neoplasms+"); (MH "Palliative Care"); Neoplasm*; (MH "Cancer Fatigue") OR (MH 
"Neoplasms+").  Footnote chasing was used to identify any further studies [20]. 
Selection Criteria 
Studies published in English with a stated study purpose to evaluate the psychometric 
properties of a CRF instrument were eligible for inclusion. People with cancer were the population 
of interest. Studies were included in the review if study participants met the following inclusion 
criteria: 1) aged 18 or more; 2) diagnosed with any type of cancer; 3) any stage of cancer; 4) in the 
case of mixed patient populations, studies were included if more than half of the participants were 
 
 
diagnosed with cancer. Exclusion criteria were protocol papers and conference abstracts; single-item 
scales such as visual analogue scales (VAS) and fatigue subscales that were part of quality of life 
scales. 
Assessment of measurement properties of CRF Scales:  
Upon retrieval of applicable studies, CRF scales were evaluated to determine dimensionality, 
(unidimensional that produces one overall fatigue score versus multidimensional that produces 
subscales score with or without an overall fatigue score), number of items, and method of 
administration. The psychometric properties of CRF scales of studies included in the review were 
assessed using Terwee et al.’s [19] quality assessment criteria (Supplementary Table S1). These 
criteria specifically address eight measurement properties: content validity, internal consistency, 
criterion validity, construct validity, reproducibility, responsiveness, floor and ceiling effects, and 
interpretability. Using the descriptors provided by Terwee et al. [19], the eight criteria were applied 
to each CRF scales within the review and rated as positive (+); indeterminate (?); negative (-); or ‘0’, 
no information available.  
For ease of interpretation, this review is reported in two sections. Section One addresses 
Terwee et al.’s [19]  quality assessment criteria to evaluate each study’s report of the CRF scales. 
Section Two reviewed the scales’ characteristics, such as the number of items, dimensions of fatigue, 
scoring system, administration time, the reporting period for the fatigue assessed, and the quality 
assessment of the scales. Unidimensional and multidimensional scales are presented separately.  
Findings 
The search strategy identified 2546 studies, which were screened by abstract and title. Based 
on the inclusion/exclusion criteria, 71 studies employing 25 different scales were included in the 
review (Figure 1). There were 7 unidimensional and 18 multidimensional scales; the former produced 
an overall fatigue score, whereas the multidimensional scales produced subscale scores and an overall 
CRF score.  
 
 
The review evaluated 71 studies with five studies reporting more than one scale: four studies 
evaluated two scales [21–24] and one study evaluated three scales [25]. Each scale in each study was 
evaluated separately. To account for studies that evaluated multiple CRF scales, the denominator for 
reporting percentages was 77 studies rather than 71 (66 studies reporting the psychometric properties 
of one CRF scales, 4 studies reporting two scales, and one study reporting three scales). 
Seventy-one psychometric studies involving 17,794 mixed cancer patients were included in 
this review (See table 1 for a general characteristic of the studies). The sample size ranged from 120 
to 800. Study participants were diagnosed with a variety of cancers. The vast majority (n = 60 studies) 
included those with mixed cancer diagnoses. The remaining studies included women with breast 
cancer, Hodgkin’s lymphoma, prostate, head and neck, and lung cancers. Nineteen different 
definitions of CRF were identified across the studies however only 32 studies (41.5%) included a 
definition of CRF. The remaining studies stated that there was no universal definition of CRF. A 
summary of all definitions used in the studies is presented in Supplementary Table S 2.  
Section One: Overall Reporting of Quality Assessment Criteria of CRF Scales  
Psychometric properties were assessed for each CRF instrument based on the Terwee et al. 
[19], checklist (see Table 2 for a summary of the evaluation). Seventy studies (91%) received a 
positive rating in terms of content validity; six (7.8 %) were indeterminate. Only one study [26] 
provided no information about content validity. Internal consistency was reported in 71 studies 
(92%); 68 received a positive rating (88%) and three had an indeterminate rating (4%) [27–29]. Sixty-
two studies received a positive score (80.5%) for construct validity, while eight  received an 
indeterminate score (10%) [30–37]. However, six studies provided no information on internal 
consistency [26,38–42] and one study received a negative rating in terms of  construct validity [38] .  
Studies evaluated other criterion less frequently. Only 23 studies (29.8%) provided 
information about criterion validity. Of these, 16 studies demonstrated positive (21%) criterion 
validity [21,27,33,38,42–52] and just seven (9%) received an indeterminate rating [37,53–58]. The 
remaining 54 (70%) studies did not provide information related to criterion validity. Agreement was 
 
 
only assessed in two studies (2.5%) [26,59], which indicated a positive score for the instrument to 
detect minimally important changes in CRF. Reliability data was reported as being acceptable (i.e., 
at least 0.07) in 26 (34%) studies. Four studies produced an indeterminate rating (5%), and 47 (61%) 
studies did not provide any information. Responsiveness was evaluated in five studies (6.5%). One 
(1.3%) study received a positive rating for responsiveness [29], while four studies (5.2%) were rated 
as indeterminate [22,60,61]. Floor and ceiling effects were reported in five studies (6.5%); four 
receiving positive ratings (5.2%) [23],[23],[62,63] and one (1.3%) an indeterminate rating [32]. Three 
studies (3.9%) reported interpretation. Two (2.6%) received an indeterminate rating [32,64] and one 
(1.3%) a positive rating [65].  
Section Two: Scale Characteristics 
The review found seven different unidimensional scales to assess CRF (Supplementary Table S3).  
Unidimensional Scales: Twenty-six studies examined the psychometric properties of unidimensional 
scales: (a) ten explored the Brief Fatigue Inventory (BFI) scale; (b) eight used the Functional 
Assessment of Chronic Therapy-Fatigue subscale (FACT-F); (c) three studies assessed the Fatigue 
Severity Scale (FSS) scales; (d) two studies evaluated the Modified Brief Fatigue Inventory (MBFI); 
and (e) one study measured Four-Items Fatigue Scale (FIFS), Fatigue Assessment Scale (FAS) and 
Fatigue Items Bank (FIB). 
The BFI is a measure of  fatigue severity for cancer populations [53]. It consists of 9 items 
using a 11-point numerical rating scale. The original version was published in English. The reliability 
and validity were established in oncology outpatients, inpatients and healthy populations. The internal 
consistency (0.96) supports the reliability of the tool [53]. The BFI is quick and easy for participants 
to complete. This inventory  has been translated into a range of  languages, including Italian [43], 
Greek [33], German [44], Taiwan-Chinese [64], Chinese [66], Japanese [45], Korean [37], Indonesian 
[67] and Filipino [39]. The internal consistency in all translated versions of the BFI was high (between 
0.96 to 0.91) and all versions were validated for use in mixed cancer populations. The method of 
translation from the original version of BFI to other languages was done according to the forward-
 
 
backward procedures. In people with cancer, the BFI meets the quality assessment criteria for content, 
criterion, and construct validity along with internal consistency and interpretation. Further work is 
needed with regard to agreement, responsiveness and floor and ceiling effects. 
The scoring system of the BFI was modified (MBFI) from the original 0-10 point numeric 
scale to a 1-7 point scale [68]. The same 9 items were retained and validated in patients with head and 
neck cancer [19]. Two validation studies of the MBFI, showed good internal consistency of the 
subscales (coefficient alpha 0.93-0.86)[21,68]. In people with cancer, the MBFI meets the quality 
assessment criteria for content, criterion, and construct validity along with reliability and internal 
consistency. However, agreement, responsiveness, floor and ceiling effects and interpretation has not 
been reported. 
The 9 items of BFI were reduced to 4 to develop the FIFS [38]. It was tested in patients with 
different types of cancer. The FIFS did not predict fatigue over time and the reliability of the scale 
needs to be confirmed in further studies. In people with cancer, the FIFS meets the quality assessment 
criteria for content and criterion validity. Reliability, internal consistency agreement, responsiveness, 
floor and ceiling effects and interpretation have yet to be reported.  
The FACT-F is a 13-item questionnaire using a 5-point Likert scale to assess fatigue [46]. It 
has been validated for use with a variety of cancer diagnoses and treatments [46]. The original FACT-
F showed strong internal consistency (coefficient alpha 0.93-0.95) and good stability (test-retest, r 
=0.87) [46]. The FACT-F has been translated in to 57 languages using iterative forward-backward 
translation methodology [69]. Eden and Kunkel [21] validated the FACT-F with patients with head 
and neck cancer and reported good internal consistency (Cronbach’s alpha 0.87) and test-retest 
reliability (r=0.95).Other psychometric studies using the instrument translated it into Spanish [61], 
French and Dutch [70], Japanese [40], Persian [71], and Portuguese [26,72]. Internal consistency of the 
translated scales ranged from between 0.79 to 0.94. In people with cancer, the FACT-F meets the 
quality assessment criteria for content, criterion, and construct validity along with agreement, 
 
 
reliability and internal consistency. Further work, however, is needed on responsiveness, floor and 
ceiling effects, and interpretation.  
The FAS includes 10-items and uses a 5-point Likert scale to assess physical and mental 
fatigue. Even though the FAS assesses two dimensions of fatigue, it is categorized as unidimensional 
as only the overall fatigue score should be used [73,74]. De Vries et al. [75] assessed the psychometric 
properties in a working population of 560 Dutch breast cancer patients; the results showed good 
internal consistency (Cronbach’s alpha 0.89) and test-retest reliability (r=0.88). The FAS meets the 
quality assessment criteria for content and construct validity along with internal consistency and 
reliability. Further work is needed on criterion validity, agreement, responsiveness, floor and ceiling 
effects and interpretation.  
The FSS includes 9 items and uses a 7-point Likert scale. The FSS was originally validated in 
multiple sclerosis and systemic lupus erythematosus populations [76]. The psychometric properties 
were assessed in advanced cancer patients [54] and mixed cancer patients [28]. The coefficient alpha 
of the two studies ranged from 0.94 to 0.96. Based on the review findings, the FSS meets the quality 
assessment criteria for content, criterion, and construct validity along with reliability, internal 
consistency and interpretation. Agreement, responsiveness and floor and ceiling effects have not been 
reported. 
The FIB is a 72-item, 5-point Likert scale which was developed to measure CRF in a 
computerized adaptive testing format [63]. The scale was validated in 301 mixed cancer patients. The 
FIB shows good psychometric properties using Rasch analysis. The internal consistency was 0.99 
and item total correlation was between 0.51 and 0.85. The factor analysis conformed that 72 items 
were unidimensional.  The authors provided a 6-item short form FIB for use in a clinical setting. In 
people with cancer, the FIB-72 items met the quality assessment criteria for content and construct 
validity, floor and ceiling effects along with internal consistency. Further work is needed on criterion 
validity, agreement, reliability, interpretation and responsiveness. 
 
 
Multidimensional Scales: The review found 50 studies that investigated the properties of 18 
multidimensional scales of fatigue. All 18 multidimensional scales provided an overall fatigue score, 
as well as subscale scores to represent specific domains of fatigue (Supplementary Table S 4 for more 
details). 
The Multidimensional Fatigue Inventory (MFI) is a 20-item, 5-point Likert scale designed to 
measure general fatigue, physical fatigue, mental fatigue, reduced motivation and reduced activity 
[77]. The scale was originally validated in Dutch cancer patients, non-cancer chronic fatigue 
syndrome patients, army recruits and medical students [77]. Smets et al. [78] validated the MFI-20 in 
a Dutch and Scottish  patients with cancer and reported good internal consistency (coefficient alpha 
0.79 to 0.93). The MFI-20 has been translated into several languages; French [56], Chinese [57], 
Brazilian Portuguese [79], Polish [55], Hindi [80], and Swedish [81], utilising the back-translation 
process. Overall, internal consistency was acceptable in all translated versions of the MFI (between 
0.80 to 0.90). In people with cancer, the MFI-20 meets the quality assessment criteria for content, 
criterion, and construct validity along with internal consistency and interpretation. Further work is 
needed on test-retested reliability, agreement, responsiveness and floor and ceiling effects.  
The Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) is a 30-item, 5-
point Likert scale that was designed specifically for use with breast cancer patients [82]. There are 5 
subscales; physical, emotional, mental, vigour and general fatigue. Initial psychometric testing 
occurred in 224 breast cancer patients, who were undergoing chemotherapy and radiotherapy, and 
the scale demonstrated very good validity and reliability [82]. Additional psychometric studies were 
conducted in English [83], Chinese[84] and Singapore Chinese [60] and the internal consistency of the 
subscales ranged from 0.74 to 0.96. In people with cancer, the MFSI-SF met the quality assessment 
criteria for content and construct validity along with internal consistency, reliability and 
responsiveness. Criterion validity, agreement, floor and ceiling effects and interpretation were not 
reported. 
 
 
Schwartz [85] published the first version of the Schwartz Cancer Fatigue Scale (SCFS), which 
has 28-items using a 5-point Likert scale. The SCFS assess four fatigue dimensions; physical, 
cognitive, temporal and emotional and was specifically designed to measure CRF. The coefficient 
alpha for total scale score was 0.96, and subscales ranged from 0.82 to 0.93. A revised version, the 
SCFS-6 contains only 6-items, measuring the physical and perceptual dimensions of CRF and has 
shown good internal consistency (coefficient alpha 0.81 to 0.88) [86] and 0.85 [29]. The SCFS-6 was 
translated into Chinese and had good internal consistency (coefficient alpha 0.88 to 0.89) [23,25] using 
backward transitional methods. In people with cancer, the SCFS-6 met the quality assessment criteria 
for content and construct validity along with reliability, internal consistency, floor and ceiling effects 
and responsiveness. Further work is needed on criterion validity, agreement, and interpretation. 
The Fatigue Symptom Inventory (FSI) consists of 13 items that assess the intensity, duration, 
daily pattern and interference of fatigue [87]. The FSI was originally developed using a sample of 
patients with breast cancer, both during and after treatment. The internal consistency of the subscales 
had a coefficient alpha above 0.90 in all groups. Hann et al. [88] tested FSI in a mixed cancer 
population and found an overall coefficient alpha of 0.94. The FSI was translated into Chinese and 
had a Cronbach’s alpha score of between 0.70 to 0.90 [23,25]. In people with cancer, the FSI met the 
quality assessment criteria for content, criteria and construct validity as well as reliability, internal 
consistency and floor and ceiling effects. Agreement, responsiveness and interpretation have not been 
assessed. 
The original Piper Fatigue Scale consisted of 40 items [89]; reduced to 22 items in the revised 
version (PFS-R) [34]. The revised version measured four subscales: behavioural/severity, affective 
meaning, sensory and cognitive/mood. The scales were validated in 382 breast cancer survivors. 
Internal consistency was high, over 0.90. The PFS-R has been validated in eight languages. Two 
psychometric studies were conducted in Italian [30,48]. Other validation studies were performed in 
Spanish [41], Swedish [27,90], Dutch  [47], Portuguese [91], Chinese [35] and Korean [31]. All 
translated versions of the PFS-R showed good internal consistency. A further reduction in the PFS 
 
 
items was carried out to create a 12-item scale (PFS-12) [92], with the reliability of the item subscales 
being between 0.87 and 0.98. The PFS-12 measured four subscales: behavioural, affective, sensory, 
and cognitive/mood. In people with cancer, the PFS-R met the quality assessment criteria for content, 
construct, and criterion validity along with reliability and internal consistency. Further work is needed 
on agreement, responsiveness, floor and ceiling effects and interpretation. 
The Perform Questionnaire (PQ) [62] consists of 12 items and was originally developed to 
measure fatigue among Spanish-speaking cancer patients. The scale assesses three dimensions: 
physical limitations, activities of daily living, and beliefs and attitudes. The scale was validated with 
a 238 mixed cancer patient population receiving adjuvant treatment, curative treatment, and palliative 
care. The internal consistency ranged from 0.78 to 0.92. Another psychometric study conducted by 
Baró et al.[65] found an overall internal consistency of 0.94 and test-retest reliability of 0.83. The PQ 
had good validity and reliability but was only validated in Spanish. In people with cancer, the PQ 
meets the quality assessment criteria for content, and construct validity along with reliability, internal 
consistency, interpretation and floor and ceiling effects. Further work is needed on criterion validity, 
agreement and responsiveness. 
The Lee Fatigue Scales (LFS) is an 18-item scale, which was originally developed to measure 
fatigue in patients with sleep disorders and is also known as the Visual Analogue Scale for Fatigue, 
(VASF) [93]. The LFS has two subscales: fatigue (13 items) and energy (5 Items). The psychometric 
properties in cancer patients were assessed by Meek et al. [22]. The scale demonstrated good 
reliability but low stability because of sensitivity to morning and evening changes [22]. Lerdal et al. 
[32] evaluated the psychometric properties of the 13 fatigue item subscale of the LFS in 587 mixed 
cancer patients. Pearson's correlation coefficients of the LFS were deemed acceptable (test-retest r 
=0.88). In people with cancer, the LFS 13-items met the quality assessment criteria for content and 
construct validity along with internal consistency and responsiveness. Further work is needed on 
criterion validity, agreement, reliability, floor and ceiling effects and interpretation. 
 
 
The Multidimensional Assessment of Fatigue (MAF) consists of 16 items scored on a scale 
ranging from 0 to 10 and originally validated in rheumatoid arthritis patients [94]. The MAF has four 
dimensions of fatigue; severity, distress, and degree of interference in activity of daily living, and 
timing. Winstead-Fry [24], tested the MAF in a mixed cancer patient population and found adequate 
internal consistency. Additional psychometric testing was carried out in a cancer population by Meek 
et al. [22] who reported the overall coefficient alpha to be 0.88. Despite this, the MAF failed to show 
adequate construct validity in terms of a four factor structure [22]. Several studies did not recommend 
using MAF unless further validation has been performed in the cancer population [15,17]. In people 
with cancer, the MAF met the quality assessment criteria for content validity as well as internal 
consistency. Further testing of criterion and construct validity, reliability, agreement, responsiveness, 
floor and ceiling effects and interpretation is required.  
The Cancer Fatigue Scale (CFS) is a 15-item, 5-point Likert scale composed of three 
domains: physical, affective and cognitive [58]. It was validated in Japanese cancer patients. The 
reliability coefficients ranged from between 0.84 and 0.88. The construct validity showed a good 
score for the instrument (0.32 - 0.67). Okuyama et al. [95] tested the CFS in breast cancer patients 
and found Cronbach’s alpha coefficients ranged from 0.76 to 0.89. Validation was completed for the 
Japanese version only. The CFS was translated into English but not tested psychometrically. Other 
translations include Chinese [25], Dutch [96], Turkish [52] and Greek [49] with good reliability (0.74 
to 0.91). Based on the review findings, the CFS met the quality assessment criteria for content, 
construct, and criterion validity as well as internal consistency. Further work is needed on agreement, 
interpretation, floor and ceiling effects and responsiveness. 
The Hirai Cancer Fatigue Scale (HCFS) is a 15-item, 5-point Likert scale, with three 
subscales; physical, mental, and cognitive fatigue [50]. The psychometric properties were assessed in 
a mixed cancer population of 281 patients undergoing treatment. The overall Cronbach's alpha 
coefficient was 0.94, supporting internal consistency and a test-retest reliability coefficient of 0.82. 
The HCFS had high reliability and high validity based on the Japanese cancer population, but further 
 
 
validation is needed for the English version. In people with cancer, the HCFS met the quality 
assessment criteria for content, criterion, and, construct validity as well as internal consistency and 
reliability in a Japanese population. Further work is needed on agreement, responsiveness floor and 
ceiling effects and interpretation.  
The Cancer-Related Fatigue Distress Scale (CRFDS) is a 20-item scale that was originally 
investigated in a heterogenous cancer population [59]. The scale used an 11-point numerical rating 
scale to assess five domains; physical, social, psychological, cognitive, and spiritual fatigue. The scale 
has very good validity and reliability. The internal consistency reliability was 0.98. In people with 
cancer, the CRFDS met the quality assessment criteria for content and construct validity as well as 
internal consistency. The criterion validity, reliability, responsiveness, floor and ceiling effects and 
interpretation were not reported. 
The Swedish Occupational Fatigue Inventory (SOFI) is a 25-item scale that was originally 
validated in work-related fatigue studies [36]. The scale measures five fatigue domains; lack of 
energy, physical exertion, physical discomfort, lack of motivation, and sleepiness. The SOFI was 
validated in a mixed Swedish cancer population of 81 patients receiving radiotherapy. The SOFI met 
the quality assessment criteria for content and criterion as well as internal consistency, interpretation, 
and floor and ceiling effects. Further work is needed on criterion and construct validity, reliability, 
agreement, responsiveness, floor and ceiling effects and interpretation. Further psychometric analyses 
are required with a larger sample size. 
The Wu Cancer Fatigue Scale (WCFS) has two versions. The original consists of 16 items 
with a 5-point Likert scale designed to assess physical, emotional, and cognitive fatigue [42]. It was 
tested in women with breast cancer undergoing chemotherapy. The scale shows adequate reliability 
and criterion-related validity. The three-factor model was not supported by exploratory factor 
analysis. The items in the revised WCFS-9 were reduced to 9 items [51]. In people with cancer, the 
WCFS-9 meets the quality assessment criteria for content, criterion, and construct validity along with 
 
 
internal consistency. Further work is needed on agreement, reliability, responsiveness and floor and 
ceiling effects and interpretation.  
The Fatigue Functional Impact Scale (FFIS) was constructed to assess fatigue and functional 
impairment in an 8-item, 10-point Likert scale [97]. The psychometric properties were assessed in 
1355 mixed cancer patients receiving chemotherapy. The FFIS showed strong internal consistency 
with coefficient alpha scores of 0.90. In people with cancer, the FFIS met the quality assessment 
criteria for content and construct validity along with internal consistency. Criterion validity, 
agreement, reliability, floor and ceiling effects, interpretation and responsiveness were not assessed. 
The General Fatigue Scale (GFS) is a 7-item scale that assesses overall fatigue intensity, 
distress level and disruptions of daily activity, and was designed to use for randomised controlled 
trials to measure fatigue at specific time-points [98]. The scale was validated and translated into 
Chinese [98]; the Cronbach’s alpha reliability coefficient was 0.94. In people with cancer, the GFS 
met the quality assessment criteria for content validity, construct validity, internal consistency and 
reliability. Criterion validity, agreement, floor and ceiling effects, responsiveness and interpretation 
were not reported. 
Discussion 
Assessing the impact of fatigue on people with cancer is imperative for understanding this 
distressing symptom and necessary for determining the impact of interventions on CRF. This review 
is the first to perform a quality assessment of CRF scales employing Terwee’s criteria of content 
validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, 
floor and ceiling effects, and interpretability [19]. Twenty-five scales assessed fatigue in adult cancer 
patients, considerably more than earlier reviews [15,17,18,99]. The quality assessment of CRF 
indicated that content, criterion, and construct validity along with internal consistency were the most 
frequently met criteria, demonstrating that the vast majority of scales undergo at least some 
psychometric testing of validity and internal consistency reliability. On the other hand, 
reproducibility, in the form of agreement and intraclass correlation reliability, responsiveness, floor 
 
 
and ceiling effects, and interpretability are generally not assessed and/or reported as part of the 
psychometric testing. No study explored all of the Terwee et al. [19] quality assessment criteria in 
evaluating the psychometric properties of CRF scales.  
The use of Terwee et al.’s [19] guidelines for assessing the psychometric properties of CRF 
scales allows users to distinguish between and make a judgment about the most appropriate choice of 
CRF scale. While each individual quality assessment criterion is important, the Terwee assessment 
does not result in an overall psychometric rating of an scale; thus, avoiding the assumption that all of 
the quality assessment criteria are equal. Terwee et al. [19] suggested that the most important criteria 
of the nine measurement properties was content validity, as absence of content validity can impact 
all other measurement properties [100]. All of the scales in this review met the criterion for content 
validity; however, this indicator on its own, may not be helpful to researchers in selecting a CRF 
instrument.  
Although other reviews of CRF scales have been conducted [15–18], this current 
psychometric review of CRF scales adds to the literature. This review used different search terms and 
inclusion criteria and the search was conducted in additional databases compared to the previous 
reviews [15–18]. As a result, this review included more studies by using different Medical Subject 
Headings (MeSH) terms and databases. This review evaluated scales using the Terwee et al.[19] 
checklist for critical evaluation of psychometric properties for each of the studies that evaluated CRF 
scales. Hence, the current review adds new evidence by presenting each scale for CRF using well-
defined criteria of psychometric properties. The most comprehensively validated scales were the BFI, 
FACT-F, MFI-20 and PFS-R. These received positive ratings in content validity, internal consistency, 
criterion validity, construct validity and reliability. In addition, these scales have been translated and 
psychometrically tested in different languages; adding to their value for use in people with cancer. 
There are several other factors that need to be taken into consideration by researchers and 
clinicians when choosing a CRF scale. There is a need to clearly understand the phenomenon of CRF. 
Unfortunately, the lack of a consensus definition has led to the development of multiple scales 
 
 
assessing various dimensions or domains of CRF phenomena [9]. It is imperative that the conceptual 
definition of fatigue is logically consistent with operationalization of the concept. The CRF scales 
assessed within this review have different foci (e.g., some addressed fatigue severity while others 
assessed impact on function). The focus of the CRF instrument should be consistent with the research 
question. In addition, the heterogeneity of the type, the stage of cancer, treatment, and type of 
management may entail different fatigue experiences, in terms of precedence and severity; thus, 
selection of a CRF scale should consider these factors. For example, the population in which the scale 
was validated previously should be taken into consideration, as cultural contexts and beliefs may 
impact on suitability or applicability of scale items. 
There are few limitations to this review. Although this review included 71 studies using 
different Medical Subject Headings (MeSH) terms and databases, it is possible that some 
psychometrics studies were not included. This review was restricted to studies published in English. 
Other psychometric studies evaluating CRF scales published in a language other than English were 
not included in this review. 
Conclusion 
This review identified seven scales that produce an overall fatigue score and eighteen scales 
that produce fatigue subscale score with or without an overall fatigue scale score. These scales were 
drawn from 77 studies assessing fatigue in people with cancer. This paper is the first to conduct a 
quality assessment of scales used to measure CRF in people with cancer. Four scales meeting the 
most quality assessment criteria, within a cancer population, two unidimensional (BFI and FACT-F) 
and two multidimensional (MFI-20 and PFS- R). Consideration should be given when choosing an 
appropriate scale for research or clinical propose, as each scale measures different dimensions or 
aspects of CRF. The least likely criteria to be assessed included test-retest reliability, agreement, 
responsiveness, interpretation, and floor and ceiling effects. Given the importance of linking 
conceptional and operationalization of fatigue in people with cancer, recommendations to move 
 
 
forward with a universally accepted definition of fatigue would further help to advance healthcare 
science and clinical practice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: The assessment of measurement properties of CRF scale (N=77): 
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1 
Brief Fatigue Inventory (BFI) Mendoza 
et al.,  [53] 
+ + ? + 0 0 0 0 0 
2 BFI-Italian,  Catania et al.,  [43] + + + + 0 0 0 0 0 
3 BFI-Greek, Meztekd et al., [33] + + + ? 0 + 0 0 0 
4 BFI-German Radbruch et al. [44] + + + + 0 + 0 0 0 
5 BFI-Taiwanese, Lin et al., [64] + + 0 + 0 + 0 0 ? 
6 BFI-Chinese, Wang et al. [66] + + 0 + 0 0 0 0 0 
7 BFI-Japanese, Okuyama  [45] + + + + 0 0 0 0 0 
8 BFI-Korean, Yun et al., [37] + + ? ? 0 0 0 0 0 
9 BFI-Indonesian, Paramita et al[67] + + 0 + 0 0 0 0 0 
10 BFI-Filipino, Mendoza et al., [39] + 0 0 + 0 0 0 0 0 
11 MBFI, Aynehchi et al., [68] + + 0 + 0 + 0 0 0 
12 MBFI, Eden & Kunkel, [21] + + + 0 0 + 0 0 0 
13 FIFS, Davis et al., [38] ? 0 + - 0 0 0 0 0 
           
14 FACT-F, Yellen, et al, [46] + + + 0 0 + 0 0 0 
15 FACT-F, Spanish, Dapueto, et al, [61] + + 0 + 0 + ? 0 0 
16 
FACT-F, French and Dutch, Van Belle et 
al., [70] 
+ + 0 + 0 0 0 0 0 
17 FACT-F, Portuguese, Ishikawa et al., [72] + + 0 + 0 + 0 0 0 
18 FACT-F, Portuguese, Ishikawa et al., [26] 0 0 0 0 + + 0 0 0 
19 FACT-F, Japanese, Yoshimura et al., [40] + 0 0 + 0 + 0 0 0 
20 FACT-F, Persian, Meysami, et al., [71] + + 0 + 0 + 0 0 0 
21 FACT-F, Eden & Kunkel [21] + + + 0 0 + 0 0 0 
           
22 
Fatigue Assessment Scale (FAS), De Vries 
et al [75] 
+ + 0 + 0 + 0 0 0 
           
23 
Fatigue Severity Scale FSS, Winstead-Fry 
P.,[24] 
+ + 0 + 0 0 0 0 0 
24 FSS, Stone et al, [54] ? + ? + 0 + 0 0 0 
25 FSS, Stone et al, [28] ? ? 0 0 0 + 0 0 0 
26 Fatigue items bank (FIB) Lai et al, [63] + + 0 + 0 0 0 + 0 
 Multidimensional instrument          
27 Multidimensional Fatigue Inventory (MFI-
20) MFI-20-Dutch, Smets et al., [77]  
+ + 0 + 0 0 0 0 0 
28 MFI-20 English, Smets et al. [78]  + + 0 + 0 0 0 0 0 
29 MFI-20 Brazilian, Portuguese Baptista et al. 
[79] 
+ + 0 + 0 0 0 0 0 
30 MFI-20 Polish, Buss et al. [55]  + + ? + 0 0 0 0 0 
31 MFI-20 Swedish, Lundh et al. [81]  ? + 0 + 0 0 0 0 0 
 
 
32 MFI-20 French, Fillion et al., [56]  + + ? + 0 0 0 0 0 
33 MFI-20 Hindi, Chandel et al. [80]  + + 0 + 0 0 0 0 0 
34 MFI-20 Chinese , Tian & Hong [57] + + ? + 0 0 0 0 0 
           
35 Fatigue Symptom Inventory-Short Form 
Stein et al., [82] 
+ + 0 + 0 + 0 0 0 
36 MFSI-SF Stein et al.,  [83] + + 0 + 0 0 0 0 0 
37 MFSI-SF-C Pien et al.,  [84]  + + 0 + 0 + 0 0 0 
38 MFSI-SF-C Chan et al.,  [60]  + + 0 + 0 + ? 0 0 
           
39 Schwartz Cancer Fatigue Scale SCFS 
Schwartz,[85]  
+ + 0 + 0 0 0 0 0 
40 SCFS-R, Schwartz & Meek, [86] + + 0 + 0 0 0 0 0 
41 SCFS-R Schwartz et al., [29] + ? 0 0 0 ? + 0 0 
42 SCFS-R Chinese, Shun et al. [25]  + + 0 + 0 0 0 0 0 
43 SCFS-R Chinese Shun et al. [23]  + + 0 + 0 ? 0 + 0 
           
44 Fatigue Symptom Inventory FSI, Hann et al  
[87] 
+ + 0 + 0 0 0 0 0 
45 FSI Hann et al [88] + + 0 + 0 0 0 0 0 
46 FSI- Chinese, Shun, et al. [25]  + + 0 + 0 0 0 0 0 
47 FSI- Chinese, Shun, et al. [23] + + 0 + 0 ? 0 + 0 
           
48 Piper Fatigue Scale-Revised (PFS-R) Piper 
et al. [34]  
+ + 0 ? 0 ? 0 0 0 
49 PFS-R Korean, Lee [31] + + 0 ? 0 + 0 0 0 
50 PFS-R Spanish, Cantarero-Villanueva et al., 
[41]  
+ 0 0 + 0 0 0 0 0 
51 PFS-R Swedish, Jakobsson et al, [27]  + + + + 0 0 0 0 0 
52 PFS-R Swedish, Lundgren-Nilsson, et al., 
[90] 
? ? 0 + 0 0 0 0 0 
53 PFS-R Dutch, Dagnelie et al. [47]  + + + + 0 0 0 0 0 
54 PFS-R Brazilian, Mota et al. [91] + + 0 + 0 0 0 0 0 
55 PFS-R Italian Giacalone et al. [48]  + + + + 0 0 0 0 0 
56 PFS-R Italian, Annunziata et al. [30]  + + 0 ? 0 0 0 0 0 
57 PFS-R Chinese So et al., [35]  ? + 0 ? 0 0 0 0 0 
58 PFS-12 Reeve et al. [92]  + + 0 + 0 0 0 0 0 
           
59 Perform Questionnaire Baró et al., [62]  + + 0 + 0 0 0 + 0 
60 PQ, Baró et al., [65]  + + 0 + 0 + 0 0 + 
           
61 Lee Fatigue Scale (LFS) Meek et al., [22]  + + 0 + 0 0 ? 0 0 
62 Lee Fatigue Scale (LFS) Lerdal et al., [32] 
only 13-items of fatigue.  
+ + 0 ? 0 + 0 ? ? 
           
63 Multidimensional Assessment of Fatigue 
(MAF) Meek et al. [22] 
+ + 0 + 0 0 ? 0 0 
64 MAF Winstead-Fry [24] + + 0 + 0 0 0 0 0 
           
65 Cancer Fatigue Scale (CFS) Okuyama et 
al., [58]  
+ + ? + 0 + 0 0 0 
66 CFS -J Okuyama et al., [95] + + 0 + 0 0 0 0 0 
 
 
67 CFS- Chinese, Shun et al., [25] + + 0 + 0 0 0 0 0 
68 CFS- Dutch, Kröz et al., [96]  + + 0 + 0 0 0 0 0 
69 CFS- Turkish, ŞAHİN, et al., [52]  + + + + 0 + 0 0 0 
70 CFS- Greek Charalambous, et al., [49]   + + + + 0 + 0 0 0 
           
71 Hirai Cancer Fatigue Scale Hirai et al., [50] + + + + 0 + 0 0 0 
           
72 Cancer-Related Fatigue Distress Scale 
(CRFDS) Holley [59] 
+ + 0 + + 0 0 0 0 
           
73 Swedish Occupational Fatigue Inventory 
Åhsberg & Fürst [36]   
+ + 0 ? 0 0 0 0 0 
           
74 16-item scale (WCFS), Wu & McSweeney, 
[42] 
+ 0 + + 0 0 0 0 0 
75 Wu Cancer Fatigue Scale (WCFS-9) Wu et 
al., [51] 
+ + + + 0 0 0 0 0 
           
76 Fatigue Functional Impact Scale (FFIS)  
Cella et al., [97] 
+ + 0 + 0 0 0 0 0 
           
77 General Fatigue Scale (GFS), Chou et al., 
[98] 
+ + 0 + 0 + 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1: Quality criteria for measurement properties of scales 
 Property  Definition  Quality Criteria  
1 Content validity The amount to which the 
domain of Interest is 
comprehensively 
sampled by the items in 
the questionnaire 
+ 
 
A clear description is provided of the measurement aim, 
the target population, the concepts that are being measured, 
and the item selection AND target population and 
(investigators OR experts) were involved in item selection ; 
? 
A clear description of above-mentioned aspects is missing, 
OR only target Population involved OR doubtful design or 
method; 
- No target population involvement; 
0 No information found on target population involvement . 
2 Internal 
Consistency 
 
The amount to which 
items in a (sub) scale Are 
intercorrelated, so 
measuring the same 
construct 
+ 
 
Factor analyses performed on adequate sample size (7 
* # items and> 100) AND Cronbach's alpha (s) 
calculated per dimension AND Cronbach's alpha (s) 
Between 0.70 and 0.95 ; 
? No factor analysis OR doubtful design or method; 
- Cronbach's alpha (s)! 0.70 or O0.95, despite adequate 
design and method ; 
0 No information found on internal consistency . 
3 Criterion 
validity 
The extent to which 
scores on a Particular 
questionnaire refer to a 
gold Standard 
+ Convincing arguments that gold standard is '' gold '' 
AND correlation with gold standard> 0.70 ; 
? No convincing arguments that gold standard is '' gold 
'' OR doubtful design or Method ; 
- Correlation with gold standard! 0.70, continuous 
adequate design and method; 
0 No information found on criterion validity. 
4 Construct 
validity 
The amount to which 
scores on a Particular 
questionnaire refer to 
other Measures in a 
manner that is 
consistent with 
theoretically derived 
hypotheses Relating 
the concepts that are 
being measured 
+ Specific hypotheses were formed and at least 75% of 
the results are in accordance with these hypotheses ; 
? Doubtful design or method (eg, no hypotheses 
- Less than 75% of hypotheses were confirmed, despite 
adequate design and Methods ; 
0 No information found on construct validation. 
5 Reproducibility    
 5.1. Agreement The amount to which 
the scores on repeated 
measures are close to 
each other (absolute 
measurement error) 
+ MIC! SDC OR MIC outside the LOA OR convicting 
arguments that agreement is acceptable ; 
? Doubtful design or method OR (MIC not defined 
AND no convincing arguments that agreement is 
acceptable 
- MIC> SDC OR MIC equals or inside LOA, despite 
adequate design and method; 
0 No information found on agreement. 
 5.2. Reliability The amount to which 
patients can be 
+ ICC or weighted Kappa> 0.70 ; 
?  Doubtful design or method (eg, time interval not 
mentioned); 
 
 
Distinguished from 
each other, despite 
Measurement errors  
(Relative measurement 
error) 
- ICC or weighed Kappa! 0.70, despite adequate design 
and method ; 
0 No information found on reliability. 
6 Responsiveness The ability of a 
questionnaire to detect 
Clinically important 
changes over time 
 
+ SDC or SDC! MIC OR MIC outside the LOA OR 
RRO1.96 OR AUC> 0.70; 
? Doubtful design or method; 
- SDC or SDC> MIC OR MIC equals or inside LOA 
OR RR <1.96 OR AUC! 0.70, despite adequate design 
and methods 
0 No information found on responsiveness. 
7 Floor and ceiling 
Effects 
 
The number of 
responders who 
achieved the lowest or 
highest possible score 
+ <15% of the respondents achieved the highest or 
lowest possible scores;  
? Doubtful design or method; 
- <15% of the respondents achieved the highest or 
lowest possible scores, strict adequate design and 
methods ; 
0 No information found on interpretation. 
8 Interpretability The degree to which 
one can assign 
Qualitative meaning to 
quantitative scores 
 
+ Mean and SD scores presented at least four relevant 
subgroups of patients and MIC defined ; 
? 
 
Doubtful design or method OR less than four 
subgroups OR no MIC defined ; 
0 No information found on interpretation. 
* This table adapted from Terwee et al.[19] page 39 
 
 
 
 
 
 
Table S2: Characteristics of the Studies 
 Scale with references Design Fatigue 
definition 
Sample Type of 
cancer 
Time of 
intervention 
Language  Internal consistency 
Cronbach’s 
Coefficient Alpha 
Test & 
Retest 
Correlation 
coefficient 
 Unidimensional Scales       
 
 
1 Brief Fatigue Inventory (BFI) Mendoza et 
al., [53] USA 
Cross-
sectional 
Not 
given 
305 Mixed Cancer 
Patient 
Not specify English α 0.96  
2 BFI-Italian,  Catania et al., [43]  
Italy 
Cross-
sectional 
Not 
given 
341 Mixed Cancer 
Patient 
Mixed Italian  α 0.94  
3 BFI-Greek, Meztekd et al., [33]  
Greek 
Longitudinal Not 
given 
102 Mixed Cancer 
Patient 
Mixed Greek α 0.95  
4 BFI-German Radbruch et al. [44] 
 Germany 
Longitudinal Def (2) 117 Mixed Cancer 
Patient 
Not specify German α 0.91  
5 BFI-Taiwanese, Lin et al., [64]  
Taiwan 
Longitudinal Def (1) 439 Mixed cancer 
Patients  
Not specify Chinese 
(Taiwanese) 
α 0.96  
6 BFI-Chinese, Wang et al. [66]  
China 
Cross-
sectional 
Not 
given 
249 Mixed cancer 
Patients  
Mixed Chinese α 0.86 to 0.91  
7 BFI-Japanese, Okuyama [45]  
Japan 
Cross-
sectional 
Not 
given 
252 Mixed cancer 
Patients 
Mixed Japanese  α 0.96  
8 BFI-Korean, Yun et al., [37]  
Korea  
Cross-
sectional 
Not 
given 
178 Mixed cancer 
Patients 
Not specify Korean α 0.95  
9 BFI-Indonesian, Paramita et al., [67] 
Indonesia 
Cross-
sectional 
Not 
given 
121 Mixed cancer 
Patients 
Not specify Indonesian α 0.95  
10 BFI-Filipino, Mendoza et al., [39] 
Philippines 
Cross-
sectional 
Not 
given 
206 Mixed cancer 
Patients 
Mixed Filipino α 0.95  
11 MBFI, Aynehchi et al., [68]  
USA 
Longitudinal Not 
given 
52 Head and Neck 
cancer 
Mixed English α 0.938 Test & 
Retest  
r =0.814 
12 MBFI, Eden & Kunkel, [21]  
USA 
Longitudinal Def 18 65 Head and neck 
skin and thyroid 
cancer  
Mixed English α 0.869 Test & 
Retest  
r =0.865 
13 Fatigue Functional Impact Scale (FFIS), 
Davis et al., [38]  
USA  
Longitudinal Def (3) 65 Mixed advanced 
cancer Patients 
Not specify English   
 
 
          
14 Functional Assessment of Chronic 
Therapy-Fatigue (FACT- F) Yellen, et al. 
[46] 
USA 
Longitudinal Def 4 49 Mixed Cancer 
Patient 
Mixed English  α 0.90 
C. α 0.93 to 0.95 
Test & Retest  
r =0.87  
15 FACT- F, French and Dutch Van Belle et 
al., [70] Belgium 
Cross-
sectional 
Def 5 834 Mixed Cancer 
Patient 
Mixed French and 
Dutch  
α 0.94  
16 FACT-F, Spanish  
Dapueto, et al, [61] Uruguay 
Longitudinal Def 4 79 Mixed cancer 
patients  
Mixed Spanish α 0.88  
17 FACT-F, Portuguese Ishikawa et al., [72] 
Brazil 
Longitudinal Not 
given 
270 Mixed cancer 
patients  
Mixed Portuguese α 0.92  
18 FACT-F, Portuguese Ishikawa et al., [26] 
Brazil 
Longitudinal Not 
given 
85 Mixed cancer 
patients  
Mixed Portuguese α 0.79 Test & Retest  
r = 0.85 
19 FACT- F, Japanese Yoshimura et al., [40] 
Japan  
Cross-
sectional 
Not 
given 
180 Lung cancer  Not specify Japanese α 0.93 Test-retest  
r =0.43-0.70 
20 FACT-F, Persian Meysami, et al., [71] 
 Iran  
Longitudinal Not 
given 
208 Breast cancer Completed 
treatment  
Persian α 0.91 Test-retest  
r =0.91 
21 FACT-F, Eden & Kunkel, [21]  
USA  
Longitudinal Def 18 65 Head and neck 
skin and thyroid 
cancer  
Mixed English α 0.911 Test & Retest  
r =0.951 
          
22 Fatigue Assessment Scale (FAS) De Vries 
et al [75] 
 Netherland 
Longitudinal  Not 
given 
204 Breast cancer  Not specify Dutch α 0.88 to 0.90 Test & Retest  
r =0.87 and r 
=0.88 
          
23 Fatigue Severity Scale (FSS) Winstead-
Fry P., [24] USA 
Cross-
sectional 
Def 17 131 Mixed cancer 
Patients 
Not specify English α =0.95  
24 FSS, Stone et al, [54] UK Longitudinal Def 6 95 Mixed advanced 
cancer Patients 
Not specify English α =0.94 Test-retest 
reliability 
Calculated by 
measurement 
error was 4.7 
25 FSS, Stone et al, [28] UK Longitudinal Def 7 227 Mixed cancer 
Patients 
Not specify English α =0.96 Test-retest 
reliability 
Calculated by 
measurement 
error was 4.7 
unites 
(satisfactory) 
 
 
26 Fatigue Items Bank (FIB) Lai et al, [63] 
USA 
Cross-
sectional 
Def 11 301 Mixed cancer 
patients 
Not specify English  
 
α =0.96  
          
 Multidimensional Scales         
27 Multidimensional Fatigue Inventory 
(MFI-20) Dutch, Smets et al., [77] 
Netherland 
Cross-
sectional 
Not 
given 
111 Mixed cancer 
Patients 
Receiving 
Radiotherapy 
Dutch α 0.84  
28 
MFI-20 English, Smets et al. [78] 
Netherland and UK 
Cross-
sectional 
Not 
given 
98 
Dutch  
116 
Scottish 
Mixed cancer 
Patients 
Receiving 
Radiotherapy 
English, 
Dutch  
Overall 0.79-0.93 
F.A. (0.98 
Dutch), 0.97 
Scottish) 
 α 0.83  
29 MFI-20 Brazilian, Portuguese Baptista et 
al. [79] Brazil 
Cross-
sectional 
Not 
given 
200 Hodgkin's 
lymphoma 
Completed 
treatment 
Brazilian 
Portuguese  
α 0.84 
α 0.59 to 0.81. 
 
30 MFI-20 Polish, Buss et al. [55] Poland Cross-
sectional 
Def 1 340 Mixed cancer 
patients  
Not specify Polish α 0.90 
α 0.57 to 0.81 
 
31 MFI-20 Swedish, Lundh et al. [81] 
Sweden 
Cross-
sectional 
Not 
given 
584 Mixed cancer 
Patients  
Mixed Swedish α 0.67 to 0.94  
32 MFI-20 French, Fillion et al., [56]  
French 
Cross-
sectional 
Not 
given 
604 
 
277 Breast 
327prostate 
Mixed French Over all α 0.90 
α 0.68 to 0.89 
 
33 MFI-20 Hindi, Chandel et al. [80]  
India 
Cross-
sectional 
Not 
given 
200 Head and 
neck, Breast, 
cervical  
Mixed Hindi Over all α 0.8 
 α 0.71 to 0.82 
 
34 MFI-20 Chinese , Tian & Hong [57] 
 China 
Cross-
sectional 
Not 
given 
385 Mixed cancer 
Patients 
undergoing 
chemotherapy 
Chinese α 0.87 
α .71 to .82 
 
          
35 Multidimensional Fatigue Symptom 
Inventory-Short Form (MFSI-SF), Stein 
et al., [82] USA 
Longitudi
nal 
Def 9 224 Breast cancer Mixed English α 0.90 to 0.96 r=0.21 -
0.82 
36 MFSI-SF, Stein et al., [83] USA Cross-
sectional 
Not 
given 
304 Mixed cancer 
Patients 
undergoing 
chemotherapy 
English  α 0.85 to 0.960 10 
37 MFSI-SF Chinese Pien et al.,  [84]  
China 
Cross-
sectional 
Def 8 107 Mixed cancer 
Patients 
Not specify Chinese Over all α 0.93 
α 0.83 to 0.92 
 
38 MFSI-SF Chinese Chan et al.,  [60]  
Singapore 
Longitudi
nal 
Not 
given 
246 Breast cancer 
and lymphoma 
patients 
undergoing 
Chemotherapy 
Chinese 
Singapore 
α = 0.749 to 0.944 r=0.005 -
0.185 
 
 
poorly 
correlated 
          
39 Schwartz Cancer Fatigue Scale (SCFS) 
Schwartz,[85] USA  
Cross-
sectional 
Def 11 166 Mixed cancer 
Patients 
Mixed English  Over all α 0.96 
α 0.82 to 0.93 
 
40 SCFS-R, Schwartz & Meek, [86]  
USA 
Cross-
sectional 
Not 
given 
303 Mixed cancer 
Patients 
Mixed English  Over all α 0.90 
α 0.81 to 0.88 
 
41 SCFS-R Schwartz et al., [29] USA Longitudi
nal 
Not 
given 
226 Mixed cancer 
Patients 
Before chemo 
and after chemo 
English  Over all C. α 0.85  
42 SCFS-R Chinese, Shun et al. [25]  China Cross-
sectional 
Def 10 243 Mixed cancer 
Patients 
Mixed Chinese Over all α 0.88 
α 0.81 to 0.90 
 
43 SCFS-R Chinese Shun et al. [23]  China Longitudi
nal 
Not 
given 
148 Mixed cancer 
Patients 
Mixed Chinese Over all α =0.89 
 
 
          
44 Fatigue Symptom Inventory (FSI), Hann 
et al  [87] USA 
Cross-
sectional 
Not 
given 
230 
  
Breast cancer  Mixed English Over all α = 0.90  
45 FSI Hann et al [88] USA Cross-
sectional 
Not 
given 
270 Mixed cancer 
patients   
Not specify English  Over all α = 0.94  
46 FSI- Chinese, Shun, et al. [25]  
China 
Cross-
sectional 
Def 10 243 Mixed cancer 
Patients 
Mixed Chinese Over all α < 0.90 
 
 
47 FSI- Chinese, Shun, et al. [23]  
China 
Longitudi
nal 
Not 
given 
148 Mixed cancer 
Patients 
Mixed Chinese Over all α =0.70 
 
 
          
48 Piper Fatigue Scale-Revised 
(PFS-R) Piper et al. [34] USA 
Cross-
sectional 
Not 
given 
382 Breast cancer 
patients  
Completed 
treatment 
English  α 0.92 to 0.96  
49 PFS-R Korean, Lee [31] Korea  Cross-
sectional 
Not 
given 
122 Breast cancer 
patients 
Mixed Korean α 0.84 to 0.93  
50 PFS-R Spanish, Cantarero-Villanueva et 
al., [41] Spain 
Cross-
sectional 
Not 
given 
111 Breast cancer 
patients 
Completed 
treatment 
Spanish Over all α 0.89 (r < 0.86) 
51 PFS-R Swedish, Jakobsson et al, [27]  
Sweden 
Cross-
sectional 
Not 
given 
196 Mixed cancer 
Patients 
undergoing 
Radiotherapy 
Swedish Over all α 0.98 
α 0.93 to 0.97 
 
52 
PFS-R Swedish, Lundgren-Nilsson, et al., 
[90] Sweden 
Cross-
sectional 
Not 
given 
196 
Mixed cancer 
Patients 
undergoing 
Radiotherapy 
Swedish  
Construct 
validity 
reported by 
Rasch 
analyses 
 
 
53 PFS-R Dutch, Dagnelie et al. [47] 
Netherlands 
Cross-
sectional 
Not 
given 
64 Lung and 
Breast cancer  
Before 
Radiotherapy 
Dutch Over all α >0.90  
54 PFS-R Brazilian, Mota et al. [91] Brazil  Cross-
sectional 
Not 
given 
584 Mixed cancer 
Patients 
Mixed Portuguese Over all α 0.841 to 
0.943 
 
55 PFS-R Italian Giacalone et al. [48]  Italy  Cross-
sectional 
Def 10 115 Mixed cancer 
patient  
Not specify Italian Over all α =95 
α 0.80 to 0.94 
r=0.77 
56 PFS-R Italian, Annunziata et al. [30]  Italy  Cross-
sectional 
Def 10 100 Mixed cancer 
Patients 
Not specify Italian Over all α =95 
α 0.88 to 0.91 
 
57 PFS-R Chinese So et al., [35] China Cross-
sectional 
Def 19 157 Mixed cancer 
Patients 
Mixed Chinese Over all α 0.89 to 
0.93 
 
          
58 PFS-12 Reeve et al. [92] - USA 
 
Longitudi
nal 
Def 12 799 Breast cancer 
survivors  
Completed 
treatment 
English  Over all α >0.80 
α 0.87 to 0.89 
 
          
59  Perform Questionnaire (PQ) Baró et al., 
[62] Spain 
Cross-
sectional 
Def 10 238 Mixed cancer 
patients  
Mixed Spanish α 0.73 to 0.92  
60 PQ, Baró et al., [65] Spain Longitudi
nal 
Def 13 437 Mixed cancer 
patients 
Mixed Spanish Over all α >0.94 
α 0.80 to 0.90 
r=0.83 
          
61 Lee Fatigue Scale (LFS) Meek et al., [22]  
USA 
Cross-
sectional 
Not 
given 
212 Mixed cancer 
patients 
Mixed English  Over all α 
The variance did 
not support 
instrument constrict 
validity  
 
62 Lee Fatigue Scale (LFS) single fatigue 
only used Lerdal et al., [32]-USA 
Longitud
inal 
Not 
given  
587 Mixed cancer 
Patients 
Mixed English  Over all α =0.89 
 
Test & 
Retest  
r=0.88  
          
63 Multidimensional Assessment of Fatigue 
(MAF), Meek et al. [22] USA 
Cross-
sectional 
Not 
given 
212 Mixed cancer 
patients 
Mixed English  Over all α =0.88 
 
 
64 MAF, Winstead-Fry [24]USA Cross-
sectional 
Def 17 131 Mixed cancer 
Patients 
Not specify English Over all α =0.89  
          
65 Cancer Fatigue Scale (CFS) Okuyama et 
al., [58] Japan 
Longitudi
nal 
Def 14 307 Mixed cancer 
Patients 
Not specify Japanese  Over all α = 0.88 
0.84 to 0.88 
r=0.32-
0.67 
 
 
66 CFS -J Okuyama et al., [95] Japan Cross-
sectional 
Not 
given 
134 Breast cancer Completed 
treatment 
Japanese 0.76 to 0.89  
67 CFS- Chinese, Shun et al., [25] China Cross-
sectional 
Def 10 243 Mixed cancer 
Patients 
Mixed Chinese Over all α =0.83 
 
 
68 CFS- Dutch, Kröz et al., [96] Germany Longitudi
nal 
Def 15 114  
 
57 healthy 
persons 57 
mixed cancer 
patients 
Mixed German 
(Dutch) 
Over all α =0.94 
 
  
r= 0.82 
69 CFS- Turkish, ŞAHİN, et al., [52] Turkey Longitudi
nal 
Def 15 80 Breast cancer Completed 
treatment 
Turkish Over all α =0.74 
 
ICC 0.95 
70 CFS- Greek Charalambous, et al., [49] 
Greek  
Cross-
sectional 
Def 18 148 Prostate cancer  Completed 
treatment 
Greek Over all α =0.916 r = 0.79, p 
<0.001) 
          
71 Hirai Cancer Fatigue Scale (HCFS) Hirai 
et al., [50]  USA 
Longitudi
nal 
Not 
given 
281 Mixed cancer 
Patients 
Mixed Japanese Over all α =0.977 r = .589-
0.913 
          
72 Cancer-Related Fatigue Distress Scale 
(CRFDS) Holley [59] USA 
Cross-
sectional 
Not 
given 
221 Mixed cancer 
Patients 
Mixed English  Over all α =0.943 (r = 0.65) 
          
73 Swedish Occupational Fatigue Inventory 
Åhsberg & Fürst [36]  Sweden 
Cross-
sectional 
Not 
given 
81 Mixed cancer 
patients  
undergoing 
radiotherapy 
Swedish α 0.73 to 0.97  
          
74 16-item scale (WCFS), Wu & 
McSweeney, [42] - USA 
Cross-
sectional 
Def 3 82 Breast 
carcinoma  
undergoing 
Chemo 
English  Over all α >0.95  
          
75 Wu Cancer Fatigue Scale (WCFS) R Wu 
et al., [51] USA 
Cross-
sectional 
Not 
given 
172 Breast cancer  undergoing 
Chemo 
English 
 
Over all α =0.91  
          
76 Fatigue Functional Impact Scale (FFIS)  
Cella et al., [97] - USA 
Cross-
sectional 
Not 
given 
401 Mixed cancer 
patients 
undergoing 
Chemo 
English 
 
Over all α =0.90  
          
77 General Fatigue Scale (GFS), Chou et al., 
[98] – Taiwan  
Longitudi
nal 
Def 17 171 Breast Cancer  undergoing 
Chemo 
Chinese -
Taiwanese 
Over all α =0.94  
 α, coefficient alpha 
 
 
 
 
Table S3: Definition of fatigue in the studies: 
 Definition 
Def :1 Fatigue is a subjective symptom and is generally thought to be related to feelings of weakness, 
tiredness, and lack of energy. [64]  
Def :2 As a multidimensional construct involving physical exhaustion, mental tiredness and a lack of 
energy [101] 
Def :3 (ICD-10), cancer-related fatigue (CRF) is defined as diminished energy, an increasing need for 
rest, limb heaviness, diminished ability to concentrate decreased interest in engaging in normal 
activities, sleep disorder, inertia, emotional liability, perceived problems with short-term 
memory, and postexertional malaise exceeding several hours and so on. [102] 
Def 4 It is defined as a subjective sensation of weakness, lack of energy, or tiredness.[61] 
Def 5 Being unusual or abnormal, absolutely disproportionate with respect to the amount of exercise or 
activity he / she has carried out, and not alleviated by resting or sleeping. [103] 
Def 6 A subjective sensation of feeling easily tired, weak or lacking in energy. [54] 
Def 7 As the subjective sensation of having reduced energy, loss of strength or becoming easily 
tired.[28] 
Def 8 Cancer-related fatigue is defined as a subjective, unusual and continuous feeling that it is cancer, 
it is associated or treatment- related and affects daily living activities [104] 
Def 9 Objectively, fatigue may be defined as a behavioral or physiologic symptom, exhibited by 
impaired physical, social, and vocational functioning.[82] 
Def 10 '' A persistent, subjective sense of tiredness related to cancer or cancer treatment that interferes 
with usual functioning’. [105] 
Def 11 (NANDA) definition, which is "an overwhelming, sustained sense of exhaustion and reduced 
capacity for physical and mental work " [106] 
Def 12 The perception of unusual tiredness that varies in pattern or severity and can affect the functional 
ability of cancer survivors [107] 
Def 13 "Distressing persistent subjective sense of physical, emotional, and / or cognitive tiredness "[108] 
Def 14 Condition characterized by a subjective feeling of a decrease in energy, and it has both physical 
and psychological aspects. [109] 
Def 15 A persistent feeling of loss of energy and performance, fatigue, increased tiredness, lack of 
energy or motivation and problems with concentration. [110] 
Def 16 "Fatigue is a subjective state of overwhelming and sustained exhaustion and decreased capacity 
for physical and mental work that is not disclosed by rest [111] 
Def 17 As a subjective experience of tiredness, decreased energy, and decreased mental and motor skills 
associated with cancer therapy. [112] 
Def 18 "A disturbing, persistent, subjective sense of physical, emotional, and / or cognitive fatigue or 
exhaustion related to cancer or cancer treatment that is not proportional to recent activity and 
interferes with usual functioning." [10] 
Def 19 "An abnormal, abnormal, or excessive whole-body tiredness disproportionate to, or unrelated to, 
activity or exertion." Page 279 [113] 
 
 
 
Table S4: Unidimensional scales 
 
 
 
 
 
 
 
 
Table S5: Multidimensional Scales 
 Scale 
N
u
m
b
er
 o
f 
it
e
m
s 
N
o
 D
o
m
a
in
 
Domain 
Fatigue 
Indication 
Type 
of 
scale 
Time to 
complet
e 
Time 
period 
assessed 
1 Multidimensional 
Fatigue Inventory 
(MFI-20) Smets et 
al., (1995) [77] 
20  
 
 
5 General, 
physical, reduced 
activity, reduced 
motivation and 
mental fatigue 
4(absence 
fatigue)  
20(maxim
um 
fatigue) 
5-
point 
Likert 
scale 
5-10 
min 
Present 
2 Multidimensional 
Fatigue Symptom 
Inventory-Short Form 
30 5 General fatigue, 
mental, physical, 
emotional and 
Vigor 
Higher 
score 
indicated 
5-
point 
Likert 
scale 
5 mints Past 7 
days 
 
Instrument 
N
u
m
b
er
 o
f 
It
em
s 
Domain 
Fatigue 
Indication 
Type of scale 
Time to 
complete 
Time 
period 
assessed 
1 Brief Fatigue 
Inventory (BFI) 
Mendoza et al., 
(1999) [53] 
9 Physical 
functional  
1-3 Mild 
4-6 Moderate 
7-10 severe 
11-Numerical 
(0-10) 
5 min Past 
24h 
2 Modified Brief 
Fatigue Inventory 
(MBFI) Aynehchi 
et al., (2013) [68] 
9 Physical 
functional  
 7-Numerical Not 
Stated  
 
Past 
24h 
3 Four-Items 
Fatigue Scale 
(FIFS), Davis et 
al., (2013)[38] 
4 Physical 
functional  
1-3 Mild 
4-6 Moderate 
7-10 severe 
10-Numerical Not 
Stated  
 
Past 
24h 
4 Functional 
Assessment of 
Chronic Therapy-
Fatigue (FACT- F) 
Yellen, et al. 
(1997) [46] 
13 Physical 
Functioning 
Cut-off 36 had 
Sensitively 
5-point Likert 
scale 
5-10 min Past 7 
days 
5 Fatigue 
Assessment Scale 
(FAS) De Vries et 
al (2010) [75] 
10 Fatigue Higher score 
indicated 
fatigue 
5-point Likert 
scale 
Not 
Stated  
 
Present 
6 Fatigue Severity 
Scale (FSS) 
Winstead-Fry P., 
(1998) [24] 
9 
 
Severity Cut-off 5 7-point Likert 
scale 
Not 
Stated  
2-3mint 
Properly 
Present 
7 Fatigue Items 
Bank (FIB) Lai et 
al, (2005) [63] 
72 
 
Fatigue Higher score 
indicated more 
fatigue 
5-point Likert 
scales 
20 min  Past 7 
days 
 
 
(MFSI-SF) Stein et 
al. (1998) [82] 
more 
fatigue 
3 Schwartz Cancer 
Fatigue Scale (SCFS) 
Schwartz, (1998) [85] 
28 4 Physical, 
emotional, 
cognitive and 
temporal  
Higher 
score 
indicated 
more 
fatigue 
5-
point 
Likert 
scale 
5 mints 2 to 3 
days 
4 Schwartz Cancer 
Fatigue Scale-6 
(SCFS-6) Schwartz 
and Meek (1999)[86] 
6 2 Physical and 
Perceptual 
Higher 
score 
indicated 
more 
fatigue 
5-
point 
Likert 
scale 
1 to 2 
min 
2 to 3 
days 
5 Fatigue Symptom 
Inventory (FSI) 
Hann et al (1998) 
[87] 
13 4 intensity, 
duration, daily 
pattern and 
interference  
Cut-off 3 
fatigue 
  
 
11-
point 
Likert 
only 
One 
with 7 
points 
5 min Past 7 
days, 
current  
6 Piper Fatigue Scale-
Revised (PFS-R) 
Piper et al. (1998) 
[34] 
22 4 behaviour / 
severity, sensory, 
mood/ cognitive 
and affective 
meaning  
0 non 
1-3 Mild 
4-6 
Moderate 
7-10 
Severe 
11-
point 
(0-10) 
numer
ic 
scales 
5 min Now 
7 PFS-12 
Reeve et al. (2013) 
[92] 
12 4 behavioral, 
sensory, mood/ 
cognitive and 
affective 
0 non 
1-3 Mild 
4-6 
Moderate 
7-10 
Severe 
11-
point 
(0-10) 
numer
ic 
scales 
>5 min Now 
8 Perform 
Questionnaire (PQ) 
Baró et al., (2009) 
[62] 
12 3 Physical 
Limitations, 
Activities of 
Daily Living, and 
Beliefs and 
Attitudes. 
Higher 
score 
indicated 
worse 
fatigue 
5-
point 
ordina
l scale 
>9 min 2 weeks 
9 Lee Fatigue Scale 
(LFS) Meek et al., 
(2000) [22] 
18 2 Fatigue and 
energy  
Higher 
score 
indicated 
greater 
fatigue 
11-
point 
(0-10) 
numer
ic 
scales 
>2 min Current 
10 Multidimensional 
Assessment of 
Fatigue (MAF) Meek 
et al., (2000) [22] 
16 4 Severity, distress, 
Interference in 
activity daily 
level, and timing  
1 (no 
fatigue)  
50 (severe 
fatigue) 
0-10 >5 min Past 7 
days 
11 Cancer Fatigue Scale 
(CFS) Okuyama et 
al., (2000) [58] 
15 3 Physical, 
affective and 
Cognitive 
1 (no 
fatigue)  
60 (severe 
fatigue) 
5-
point 
Likert 
scale 
2-3 min Current 
12 Hirai Cancer Fatigue 
Scale (HCFS) Hirai 
et al., (2015) [50] 
15 4 Physical, Mental, 
and Cognitive 
fatigue 
Higher 
score 
indicated 
greater 
fatigue 
5-
point 
Likert 
scale 
Not  
Given 
probabl
y 
2-5 min  
Current 
13 Cancer-Related 
Fatigue Distress 
23 
 
5 Physical, Social, 
Psychological, 
Higher 
score 
11-
point 
Not  Current 
 
 
Scale (CRFDS) 
Holley (2000) [59] 
Cognitive and 
Spiritual  
indicated 
severe 
fatigue 
(0-10) 
numer
ic 
scales 
Given 
probabl
y 
3-5 min 
14 Swedish 
Occupational Fatigue 
Inventory (SQFI) 
Åhsberg & Fürst 
(2001) [36] 
25 5 Lack of energy, 
Physical 
exertion, 
Physical 
discomfort Lack 
of motivation and 
Sleepiness 
Higher 
score 
indicated 
more 
fatigue 
(0-6)  
< 2 
indicted 
fatigue 
7- 
point 
Likert 
scale 
Not  
Given 
probabl
y 
5-8 min 
Current 
15 16-item scale 
(WCFS) 
Wu & McSweeney, 
(2004) [42] 
16 3 Physical 
Emotional and 
cognitive 
Higher 
score 
indicated 
more 
fatigue 
(15-75)  
5-
point 
Likert 
scale 
Not  
Given 
probabl
y 
5 min 
Past 1 
day 
16 Wu Cancer Fatigue 
Scale (WCFS) R Wu 
et al., (2006) [51] 
9 3 Physical 
Emotional and 
cognitive 
Higher 
score 
indicated 
more 
fatigue 
(9-45)  
5-
point 
Likert 
scale 
Not  
Given 
probabl
y 
2-3 min 
Past 1 
day 
17 Fatigue Functional 
Impact Scale (FFIS) 
Cella et al., (2008) 
[97] 
8 2 Fatigue and 
functional 
impairment 
Higher 
score 
indicated 
more 
fatigue 
10-
point 
numer
ic 
scales 
2-3 min Past 
Month 
18 General Fatigue Scale 
(GFS) Chou et al., 
(2016) [98] 
7 3 Intensity, 
distress, 
disruption of 
daily activities  
Higher 
score 
indicated 
more 
fatigue 
10-
point 
numer
ic 
scales 
3-5 min Past 7 
days 
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